Judah Frommer
Stock Analyst at Morgan Stanley
(3.12)
# 1,135
Out of 4,786 analysts
183
Total ratings
58.65%
Success rate
5.3%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Assumes: Equal-Weight | $120 → $100 | $88.51 | +12.98% | 1 | Mar 20, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Overweight | $46 | $18.15 | +153.44% | 1 | Mar 20, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $6.25 | +92.00% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $7.15 | +235.66% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $25.12 | -12.42% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $3.23 | +85.76% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $21.87 | +41.75% | 1 | Nov 21, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $65.60 | +61.59% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $13.03 | +168.61% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $1.26 | +931.75% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $0.88 | +242.39% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $4.30 | +830.23% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.10 | +1,081.82% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $29.52 | +1.63% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $6.65 | +245.86% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $50.96 | -1.88% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $63.82 | +120.93% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.28 | +915.63% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.36 | +561.76% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $20.47 | +7.47% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.65 | +23.89% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $2.88 | +177.78% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $13.99 | +228.81% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $1.44 | +386.11% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $10.60 | +418.87% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $76.29 | -39.70% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $78.63 | -37.68% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $945.78 | -60.88% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $65.46 | -52.64% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $75.04 | +1.28% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $87.93 | +106.98% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $75.07 | +42.53% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $116.36 | -18.36% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $21.99 | -18.14% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $74.93 | +54.82% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $114.10 | -66.70% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $152.64 | -85.59% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.69 | -48.29% | 9 | Apr 29, 2020 |
Blueprint Medicines
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $120 → $100
Current: $88.51
Upside: +12.98%
Celldex Therapeutics
Mar 20, 2025
Initiates: Overweight
Price Target: $46
Current: $18.15
Upside: +153.44%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $6.25
Upside: +92.00%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $7.15
Upside: +235.66%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $25.12
Upside: -12.42%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $3.23
Upside: +85.76%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $21.87
Upside: +41.75%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $65.60
Upside: +61.59%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $13.03
Upside: +168.61%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $1.26
Upside: +931.75%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $0.88
Upside: +242.39%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $4.30
Upside: +830.23%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.10
Upside: +1,081.82%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $29.52
Upside: +1.63%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $6.65
Upside: +245.86%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $50.96
Upside: -1.88%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $63.82
Upside: +120.93%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.28
Upside: +915.63%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.36
Upside: +561.76%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $20.47
Upside: +7.47%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.65
Upside: +23.89%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $2.88
Upside: +177.78%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $13.99
Upside: +228.81%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $1.44
Upside: +386.11%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $10.60
Upside: +418.87%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $76.29
Upside: -39.70%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $78.63
Upside: -37.68%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $945.78
Upside: -60.88%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $65.46
Upside: -52.64%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $75.04
Upside: +1.28%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $87.93
Upside: +106.98%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $75.07
Upside: +42.53%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $116.36
Upside: -18.36%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $21.99
Upside: -18.14%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $74.93
Upside: +54.82%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $114.10
Upside: -66.70%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $152.64
Upside: -85.59%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.69
Upside: -48.29%